ArticleTropical diseases, travel medicine and vaccines2026
Molecular surveillance of the Plasmodium falciparum Pfmdr1 N86Y mutation linked to antimalarial drug resistance in Mbouda, Cameroon.
Article in Tropical diseases, travel medicine and vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Resistance profile of the Plasmodium falciparum dihydropteroate synthase gene in three hospitals in the city of Ndjamena, Chad.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria, mainly caused by Plasmodium falciparum, remains a major health concern in Cameroon due to the emergence of drug-resistant parasite strains. The Plasmodium falciparum multidrug resistance 1 (Pfmdr1) gene, particularly the N86Y mutation, is a key marker associated with reduced susceptibility to several antimalarial drugs. This study investigated the prevalence of the Pfmdr1-N86Y mutation in isolates from patients attending three health facilities in the Mbouda Health District to support improved malaria control strategies in the area.
methodsThe study was conducted among patients attending three healthcare facilities in Mbouda. Three hundred and two (302) patients were recruited across these three centers and diagnosed by both rapid diagnostic test (RDT) and thick blood smear (TBS). positive samples were spotted on whatman paper. Plasmodial DNA was extracted using the chelex- 100 method. The Pfmdr1 gene was then amplified by nested PCR, visualized on a 1.3% agarose gel, and analyzed by restriction fragment length polymorphism (RFLP) using the AflIII restriction enzyme. Statistical analysis was performed with a significance threshold of 5% (p < 0.05) using SPSS software version 26, particularly employing Chi-square tests.
resultsThe prevalence of Plasmodium falciparum infection was 28.8%, with the highest burden among males, children aged 0–5 years, and adults over 35 years. Insecticide use was identified as a significant protective factor, and parasite density was higher among males and young children. The Pfmdr1 gene was detected in 95% of isolates. Analysis of the Pfmdr1-N86Y mutation revealed that 94% of alleles were wild-type (N86), 1% were mixed (N86/Y86), and no mutant alleles (Y86) were observed and 5% tested negative for this gene, which may be due to poor DNA quality, often denatured, or poor extraction, or other reasons.
conclusionThis study indicates that, the Pfmdr1 gene exhibited a frequency 95%. These results therefore highlight the importance of other types of Pfmdr1 mutations and would be necessary for the evaluation of Pfmdr1 mutations associated with parasite resistance to antimalarial drugs. Measures should be taken to delay the evolution of these mutations by changing treatment policy in the affected area if these mutations are nevertheless very high.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.